Comments
Loading...
Cyclerion Therapeutics (CYCN) Forecast
NewsEarningsCyclerion Therapeutics (CYCN) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestCyclerion Therapeutics (NASDAQ:CYCN) Stock Quotes, Forecast and News Summary
Cyclerion Therapeutics Stock (NASDAQ: CYCN) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Cyclerion Therapeutics (CYCN) stock?
You can purchase shares of Cyclerion Therapeutics (NASDAQ:CYCN) through any online brokerage.
Who are Cyclerion Therapeutics (CYCN) competitors?
Other companies in Cyclerion Therapeutics’s space includes: CERo Therapeutics Hldgs (NASDAQ:CERO), Galecto (NASDAQ:GLTO), Dermata Therapeutics (NASDAQ:DRMA), Portage Biotech (NASDAQ:PRTG) and TransCode Therapeutics (NASDAQ:RNAZ).
What is the forecast, or price target, for Cyclerion Therapeutics (CYCN) stock?
There is no analysis for Cyclerion Therapeutics to provide a consensus price target.
What is the current price for Cyclerion Therapeutics (CYCN)?
The stock price for Cyclerion Therapeutics (NASDAQ: CYCN) is $2.71 last updated February 21, 2025 at 10:06 AM EST.
Does Cyclerion Therapeutics (CYCN) pay a dividend?
There are no upcoming dividends for Cyclerion Therapeutics.
When is Cyclerion Therapeutics (NASDAQ:CYCN) reporting earnings?
Cyclerion Therapeutics’s Q1 earnings are confirmed for Tuesday, May 6, 2025.
Is Cyclerion Therapeutics (CYCN) going to split?
There is no upcoming split for Cyclerion Therapeutics.
What sector and industry does Cyclerion Therapeutics (CYCN) operate in?
Cyclerion Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.